Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Reltecimod as Compared to Placebo in Addition to Standard of Care in Patients With Sepsis-associated Acute Kidney Injury (SA-AKI)

NCT03403751 is registered in ClinicalTrials.gov with Atox Bio Ltd as lead sponsor.

NCT NCT03403751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03403751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Reltecimod as Compared to Placebo in Addition to Standard of Care in Patients With Sepsis-associated Acute Kidney Injury (SA-AKI)
Lead sponsor
Atox Bio Ltd
Phase
Phase 3
Overall status
Terminated
Start date
May 24, 2018
Completion date
December 14, 2019
Enrollment
58 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, necrotizing soft tissue infection, peritonitis